In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

Sofia Perea, Gloria Gonzalez, Annette W. Fothergill, Deanna A. Sutton, Michael G. Rinaldi

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of ≤0.5, was observed in 17% of TRB-FLU interactions, 21% of TRB-ITRA interactions, 33% of TRB-VRC interactions, and 12% of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.

Original languageEnglish (US)
Pages (from-to)1831-1833
Number of pages3
JournalJournal of clinical microbiology
Volume40
Issue number5
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles'. Together they form a unique fingerprint.

Cite this